Silence Therapeutics (SLN) Assets (2018 - 2026)

Silence Therapeutics' Assets history runs 9 years deep, the most recent figure standing at $115.1 million for Q1 2026.

• In Q1 2026, Assets fell 37.87% year-over-year to $115.1 million; the TTM figure through Mar 2026 stood at $115.1 million (down 37.87% YoY), while the FY2025 annual figure was $131.4 million, down 35.13% from the prior year.
• Assets came in at $115.1 million for Q1 2026 at Silence Therapeutics, down from $131.4 million in the prior quarter.
• In the past five years, Assets ranged from a high of $246.6 million in Q1 2024 to a low of $105.0 million in Q2 2022.
• A 5-year average of $153.9 million and a median of $131.4 million in 2025 frame the typical range for Assets.
• Across the five-year window, Assets soared 115.03% in 2024 and plunged 37.87% in 2026, its largest moves.
• Silence Therapeutics' Assets stood at $126.1 million in 2022, then decreased by 7.65% to $116.4 million in 2023, then soared by 74.01% to $202.6 million in 2024, then slumped by 35.13% to $131.4 million in 2025, then slipped by 12.42% to $115.1 million in 2026.
• According to Business Quant data, Assets over the past three periods registered $115.1 million, $131.4 million, and $146.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison